Articles On Micro-X (ASX:MX1)
| Title | Source | Codes | Date |
|---|---|---|---|
|
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | MX1 | 2 years ago |
|
FNArena Corporate Results Monitor – 31-08-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AIM)) - Ai-Media Technologies ((AMI)) - Aurelia Metals ((BXB)) - Brambles ((C79)) - Chrysos ((CYG)) - Coventry Group ((DDR)) - Dicker Data ((EML)) - E... |
FNArena | MX1 | 2 years ago |
|
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | MX1 | 2 years ago |
|
Curvebeam AI CEO says medical devices beat drugs to revenue, massive market in medical imaging
Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown Despite the recent rally, the ASX Healthcare Index (XHJ) is... |
Stockhead | MX1 | 2 years ago |
|
Strokes cost the Australian economy billions, but these biotech players could change that
Stroke has long been recognised as being among Australia’s most costly disease groups. It occurs when a blood vessel supplying blood to the brain either suddenly becomes blocked or ruptures and begins to bleed which can result in part of t... |
Stockhead | MX1 | 2 years ago |
|
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | MX1 | 2 years ago |
|
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks rise as Volpara records third quarter of positive cashflow
ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun... |
Stockhead | MX1 | 2 years ago |
|
TMH Market Close: Rinehart in court over royalties at Hope Downs, Pilbara
Lawyers for descendants of the late Peter Wright were first on the stand today, taking on Gina Rinehart over ownership and royalties relating to Hope Downs iron ore operations in the Pilbara. It’s day one of the Supreme Court of Western... |
themarketherald.com.au | MX1 | 2 years ago |
|
Micro-X [ASX:MX1] Secures $21 Million Contract Extension to Build Self-Screening Airport Checks
Micro-X shares were up by 28.57% after the announcement today of the extension of its contract with the DHS to build and test a self-screening airport module. The contract is worth up to AU$21 million and will see testing that will eventual... |
MoneyMorning | MX1 | 2 years ago |
|
Micro-X subsidiary awarded contract extension to develop passenger self-screening modules for US airports
This content is created by Smallcaps Authors. [Author : Imelda Cotton] South Australian x-ray technology developer Micro-X (ASX: MX1) has confirmed its subsidiary company Micro-X Inc has been awarded a $21 million contract extension with... |
SmallCaps | MX1 | 2 years ago |
|
ASX up 0.14% at noon: ACCC delays ANZ-Suncorp merger
At noon, the S&P/ASX 200 is 0.14 per cent higher at 7,324. Suncorp has confirmed that the Australian Competition & Consumer Commission (ACCC) has requested additional time to review ANZ's merger with Suncorp. The ACCC asked for the... |
ShareCafe | MX1 | 2 years ago |
|
Stocks of the Hour: Micro-X, European Metals, Tamboran Resources
Micro-X (ASX:MX1) extends contract with U.S. DHS to test self-screening modules at an airport. In response, Micro-X Inc. Chief Executive Officer of Americas and Chief Scientist, Brian Gonzales, commented: “This contract extension fully fu... |
ShareCafe | MX1 | 2 years ago |
|
Stocks of the Hour: Micro-X, European Metals, Tamboran Resources
24 Jul 2023 - A snapshot of the stocks on the move, featuring Micro-X (ASX:MX1), European Metals (ASX:EMH) and Tamboran Resources (ASX:TBN). |
FNN | MX1 | 2 years ago |
|
Top 10 at 10: Positive phase 1 trials and a $21m US govt contract
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks fall in first week of FY23 as Mach 7 scores biggest deal in its history
ASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60 million Veterans contract – the most significant in its history Neuren completes recruitment for Phase II trial of NNZ-2591 in Phelan-McDer... |
Stockhead | MX1 | 2 years ago |
|
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | MX1 | 2 years ago |
|
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | MX1 | 2 years ago |
|
ASX Tech Stocks May: AI sends things that go beep soaring 11.6pc, outpacing benchmark
The ASX tech sector rallied 11.6% in May and is up 16.94% YTD, surpassing the S&P ASX 200 Audio Pixels tops May ASX tech winners following AGM comments by CEO and chairman Archer Materials performs strongly in May after key global part... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks… could be worse
ASX health stocks outperforming the broader market but remain flattish for week Several ASX health plays undertaking capital raising with more expected in H2 CY23 Micro-X successfully tests its Argus bomb detection unit opening door to US$... |
Stockhead | MX1 | 2 years ago |
|
TMH Market Close: ASX200 slips into the red, dragged by real estate and energy sectors
The ASX200 shed 8.1 points on Tuesday or 0.11 per cent, just one day after its strongest advance since mid-April. The real estate and energy sectors were the biggest drags on the market, each down around 1 per cent. In the red Ma... |
themarketherald.com.au | MX1 | 2 years ago |
|
CLOSING BELL: ASX closed 0.11% lower, because there was no one around last night to tell us what to do
ASX benchmark ends the day flat, but not for lack of trying to rise. Or fall Tech stocks fell hard at first light, but rallied to finish the day well out in front Despite a short-lived challenge from Audio Pixels, Micro-X has won the day i... |
Stockhead | MX1 | 2 years ago |
|
ASX-listed Micro-X made a crucial bomb disposal breakthrough – and the US is watching
Micro-X Argus bomb detection unit successfully field tested opening door to US$1.8 billion market The device removes need for a bomb disposal technician to get up close to a suspect package Argus has attracted attention of key defence and... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s (he’s back) Powerplays: ASX health stocks fall, Volpara ‘elephants’ strategy pays off
ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor... |
Stockhead | MX1 | 2 years ago |
|
CLOSING BELL: And with one swift tug, we all get to learn what it’s like to be pantsed by the RBA
RBA Board kicks the nation in the goolies again, demanding another 25 basis points Investors seemingly caught by surprise, tanking the market in a matter of minutes Pinnacle Minerals let off the leash by the ASX, but still ahead of the gam... |
Stockhead | MX1 | 2 years ago |
|
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | MX1 | 2 years ago |
|
Dr Boreham’s Crucible: Every sperm is sacred – and profitable
What’s wrong with our tadpoles, gentlemen? According to local fertility expert Prof John Aitken, sperm counts have roughly halved over the last 50 years and about 20 per cent of men shoot blanks. No-one’s sure why, but possible reasons incl... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks fall, Healius receives $1.52 billion takeover offer
ASX health stocks fall 0.9% in the past five days Healius receives a $1.52 billion takeover offer from Australian Clinical Labs Pharmaceutical wholesaler Sigma reports improved performance for the financial year Healthcare and life scien... |
Stockhead | MX1 | 2 years ago |
|
Why growth is a positive for the ASX medical imaging sector
The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect... |
Stockhead | MX1 | 2 years ago |
|
CLOSING BELL: $35 billion in sweet, sweet divvies suddenly makes it all seem worthwhile
ASX climbed as high as +1.3%, easing slightly to close up 0.9%. XEC Emerging Companies and Goldies duke it out to see who can close flattest. Investors are set to pocket $35 billion in dividends between now and EOFY. Do Not Adjust Your... |
Stockhead | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks fall but keep watchful eye on upcoming catalysts
ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co... |
Stockhead | MX1 | 2 years ago |
|
FNArena Corporate Results Monitor – 28-02-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABY)) - Adore Beauty ((AIM)) - Ai-Media Technologies ((AGI)) - Ainsworth Game Technology ((ART)) - Airtasker ((AKE)) - Allkem ((APM)) - APM Human Services International... |
FNArena | MX1 | 2 years ago |
|
ScoPo’s Powerplays: ASX health stocks rise, Mach 7 lands largest contract and posts record quarter
ASX health stocks rise 2.27% this week after finishing up 3.9% in January in strong start to 2023 Mach 7 posts a record quarter in sales after landing its largest ever contract in December EBR System’s pivotal trial into WiSE on schedule,... |
Stockhead | MX1 | 2 years ago |
|
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | MX1 | 2 years ago |
|
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | MX1 | 3 years ago |
|
ScoPo’s Powerplays: ASX health stocks fall as Mach7 lands its biggest customer yet
The ASX Health sector has fallen ~1.5% in its first trading week of 2023 Mach7 has surged after landing its largest ever customer contract Proteomics gets US approval for PromarkerD test for diabetic kidney disease Healthcare and life sc... |
Stockhead | MX1 | 3 years ago |
|
The A to Z of Dr Boreham’s Crucible in 2022
The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,... |
Stockhead | MX1 | 3 years ago |
|
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | MX1 | 3 years ago |
|
ASX Quarterlies: These tech and health stocks finished the quarter with a bang
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it all, we’ve wrapped up the highlights from some of the reports that caug... |
Stockhead | MX1 | 3 years ago |
|
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | MX1 | 3 years ago |
|
Webinar Recap – EZZ, ELS, MX1 & QXR
ShareCafeWebinar Recap – EZZ, ELS, MX1 & QXR Catch up on the full webinar presentations from EZZ Life Sciences (ASX: EZZ), Elsight (ASX: ELS), Micro-X (ASX: MX1) & QX Resources (ASX: QXR) Webinar Recap – EZZ, ELS, MX1 & QXRComp... |
ShareCafe | MX1 | 3 years ago |
|
Micro-X (ASX: MX1) – Webinar Presentation
ShareCafeMicro-X (ASX: MX1) – Webinar Presentation Peter Rowland – Managing Director – Mirco-X is a leading global revolution company in medical and security imaging products, which designs, develops, and manufactures ultra-lightweight car... |
ShareCafe | MX1 | 3 years ago |
|
Market Highlights: ASX poised for another bleak day, and 5 ASX small caps to watch on Monday
The ASX will open more than 1% lower on Monday Wall Street tumbled again on Friday on recession fears UK announced historic tax cuts Local shares are set to open much lower on Monday. At 8am AEST, the ASX 200 October futures contract is p... |
Stockhead | MX1 | 3 years ago |
|
Evening Report: 19 September, 2022
ShareCafeEvening Report: 19 September, 2022 by Paul Sanger At the closing bell, the S&P/ASX 200 was 0.28 per cent or 19.20 points lower at 6719.90. Futures The Dow Jones futures are pointing to a fall of 118 points. The S&P 500 fu... |
ShareCafe | MX1 | 3 years ago |
|
Guess which ASX medical tech share soared 37% at one point today
The Micro-X Ltd (ASX: MX1) share price exploded today on news of a $15 million investment. Micro-X shares surged 37% from 13.5 cents to 18.5 cents before retreating. The company’s shares finished the day up 26%. Let’s take a look at what... |
Motley Fool | MX1 | 3 years ago |
|
Closing Bell: Iffy ASX 200 fizzles, AIC Mines plays master of puppets with takeover target Demetallica
The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h... |
Stockhead | MX1 | 3 years ago |
|
Lunch Report: 19 September, 2022
ShareCafeLunch Report: 19 September, 2022 by Paul Sanger At noon, the S&P/ASX 200 is 0.10 per cent or 7.00 points higher at 6746.10. The SPI futures are pointing to a rise of 5 points. Best and worst performers The best-performing sec... |
ShareCafe | MX1 | 3 years ago |
|
Stocks of the Hour: 19 September, 2022
ShareCafeStocks of the Hour: 19 September, 2022 Australian hi-tech company Micro-X Ltd (ASX:MX1) a leader in x-ray technology for health and security markets globally, is pleased to announce a strategic collaboratio... |
ShareCafe | MX1 | 3 years ago |
|
Stocks of the Hour: Micro-X, IVE Group, Origin Energy
19 Sep 2022 - A snapshot of the stocks on the move featuring Micro-X (ASX:MX1), IVE Group (ASX:IGL) and Origin Energy (ASX:ORG). |
FNN | MX1 | 3 years ago |
|
Closing Bell: Local markets go ex-div and surrender; Peppermint Innovation jumps 41% and a Newtowner on me for anyone who can explain why
ASX 200 sinks 2% Small caps get crushed, down 2.5% Region, AUD and miners sink on weaker China activity The local market is being dragged to hell by mining, materials and gold stocks, which are down between 4% and 5%. The S&P/ASX... |
Stockhead | MX1 | 3 years ago |